Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CGTX | US
-0.08
-6.20%
Healthcare
Biotechnology
30/06/2024
08/06/2026
1.21
1.32
1.35
1.18
Cognition Therapeutics Inc. a clinical-stage biopharmaceutical company engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812 an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase New York.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
79.8%1 month
86.0%3 months
125.0%6 months
102.3%-
-
0.86
0.03
0.02
-0.44
-
-
-58.61M
48.56M
48.56M
-
-
-
-
-108.31
1.04
1.91
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.37
Range1M
0.45
Range3M
0.95
Rel. volume
0.72
Price X volume
995.87K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| THL Credit Inc. 6.75% Notes du | TCRX | Biotechnology | 0.9939 | 52.65M | 1.22% | n/a | 35.68% |
| Rani Therapeutics Holdings Inc. Class A Common Stock | RANI | Biotechnology | 0.8396 | 48.59M | 1.22% | n/a | 1243.32% |
| Mereo BioPharma Group plc | MREO | Biotechnology | 0.305 | 46.93M | -2.62% | n/a | 7.83% |
| Nuo Therapeutics Inc | AURX | Biotechnology | 1 | 46.60M | -13.79% | n/a | 0.00% |
| NRXP | NRXP | Biotechnology | 4.33 | 46.55M | 4.59% | n/a | -46.73% |
| INC Research Holdings Inc | INCR | Drug Manufacturers-Specialty & Generic | 0.99 | 45.31M | -2.94% | n/a | 28.90% |
| BioXcel Therapeutics Inc | BTAI | Biotechnology | 1.105 | 45.02M | 0.00% | n/a | -139.46% |
| PEPG | PEPG | Biotechnology | 1.35 | 44.00M | -4.26% | n/a | 12.52% |
| Acrivon Therapeutics Inc. | ACRV | Biotechnology | 1.41 | 43.67M | -1.40% | n/a | 1.95% |
| Entera Bio Ltd | ENTX | Biotechnology | 1.2 | 43.59M | 1.69% | n/a | 3.91% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.08 | 32.10M | -0.02% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.1 | 16.07M | 7.84% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4131 | 7.98M | -3.48% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.49 | 3.81M | 12.88% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0058 | 534.84K | n/a | -37.05% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4181 | 230.37K | 7.87% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.44 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.86 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 124.98 | 72.80 | Riskier |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 48.56M | 3.66B | Emerging |